Glenmark Pharmaceuticals Limited

Glenmark Pharmaceuticals Limited

Glenmark Pharmaceuticals Limited has announced its Q1 FY27 results, with consolidated revenue growing 23.1% YoY to Rs. 40,185 million, driven by strong execution and resilience of its business. The company reported EBITDA of Rs. 8,048 million, a 38.6% YoY growth, and PAT of Rs. 4,828 million, with a PAT margin of 11.8%. The company's India formulations revenue grew 15.5% YoY, North America revenue grew 41.1% YoY, and Emerging Markets revenue grew 27.7% YoY.

Glenmark Pharmaceuticals Limited

Glenmark Pharmaceuticals Limited has informed the Exchange regarding 'Regulation 30(5) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 - List of Officials'. The company has updated its officials authorized for determining materiality of events or information and making disclosures to the stock exchange.

Glenmark Pharmaceuticals Limited

Glenmark Pharmaceuticals Limited has announced its unaudited financial results for the quarter ended June 30, 2026, with revenue from operations at ₹24,349.93 crore and profit after tax at ₹7,356.37 crore. The company has also announced a record date of August 31, 2026, for the purpose of determining the entitlement of dividend for the AGM to be held for the Financial Year ended March 31, 2026.

Glenmark Pharmaceuticals Limited

Glenmark Pharmaceuticals Limited has submitted its unaudited financial results for the quarter ended June 30, 2026, and announced the 48th Annual General Meeting (AGM) to be held on September 11, 2026. The company also approved amendments to its policies, including the Policy on Related Party Transactions and its Materiality, and reconstituted its Risk Management Committee.

Glenmark Pharmaceuticals Limited

Glenmark Pharmaceuticals Limited has announced the launch of Sugammadex Injection, 200 mg/2 mL (100 mg/mL) and 500 mg/5 mL (100 mg/mL) Single-Dose Vials in the US market, which is expected to generate significant revenue.

Glenmark Pharmaceuticals Limited

Glenmark Pharmaceuticals Limited has informed the Exchange about the publication of a newspaper advertisement for the transfer of equity shares to the Investor Education and Protection Fund (IEPF) Authority, as per the Companies Act, 2013 and the Investor Education and Protection Fund Authority (Accounting, Audit, Transfer and Refund) Rules, 2016.

Glenmark Pharmaceuticals Limited

Glenmark Pharmaceuticals Limited has informed the Exchange about the schedule of an earnings call for the unaudited financial results for the quarter ended June 30, 2026. The call is scheduled to be held on August 03, 2026, from 8:30 am to 9:30 am IST.

Glenmark Pharmaceuticals Limited

Glenmark Pharmaceuticals Limited

Glenmark Pharmaceuticals Limited has announced the launch of Olanzapine for Injection, 10 mg/vial, Single-Dose Vial in the US market. The product is bioequivalent and therapeutically equivalent to the reference listed drug, Zyprexa IntraMuscular Injection 10 mg/vial. The launch is expected to expand access to quality and affordable treatment options for patients and healthcare providers.

Glenmark Pharmaceuticals Limited

Glenmark Pharmaceuticals Limited has informed the Exchange regarding a press release dated July 02, 2026, titled "Glenmark Advances Multi-Country Phase 3 Clinical Trial of Trastuzumab rezetecan in Platinum-Resistant Ovarian Cancer". The company announced the advancement of its multi-country Phase 3 clinical trial for Trastuzumab rezetecan, a HER2-targeted antibody drug conjugate, for patients with platinum-resistant ovarian cancer.

Glenmark Pharmaceuticals Limited

Glenmark Pharmaceuticals has informed the exchange about a U.S. FDA inspection at its manufacturing facility in Goa, India, which resulted in six observations, all of which are procedural in nature and none are repeat observations. The company does not anticipate any impact on the supply of its commercial products.

Glenmark Pharmaceuticals Limited

Glenmark Pharmaceuticals Limited has informed the Exchange about the schedule of an Analyst/Institutional Investor meeting to be conducted on June 30, 2026, in London.

Glenmark Pharmaceuticals Limited

Glenmark Pharmaceuticals Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015.